PROS1 and cancer: Immunotherapy aimed at the cancer-associated viral early proteins (HPV16 E6 and HPV16 E7) is anticipated to establish the basis for cancer-specific immunotherapy, as HPV-associated tumors persist in expressing viral proteins and presenting them to the host immune system.